WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Harnessing AI for Pharmacovigilance : Revolutionizing Drug Safety Monitoring with Advanced Technology

Mayuri G. Zore[a], Priya M. Dandekar[b], Shamli K. Ingle[c], Shivam R. Ingle[d], Shivam K. Kathale[e], Vaibhav V.Bakale[f], Atish N.Dhakane[g]

[a]Asst.Prof.Department of Pharmacy,GCP,Sakharkherda,Buldhana, 443202,India.
[b]Asst.Prof.Department of Pharmaceutics,GCP,Sakharkherda,Buldhana, 443202,India.
[c]Student,B.Pharm, SSGMCOP, Buldhana, 443001,India .
[d,e,f] Student B.Pharm,GCP, Buldhana ,443202,India .
[g]Asst.Prof.Department of Pharmaceutical Chemitry,GCP,Sakharkherda,Buldhana, 443202,India.

A B S T R A C T

The integration of artificial intelligence (AI) in pharmacovigilance (PV) marks a significant advancement in drug safety monitoring. Traditional PV methods, while foundational, face limitations such as data underestimation, delayed event identification, and the cumbersome handling of vast data volumes. AI, leveraging techniques like machine learning and natural language processing, offers transformative potential to overcome these challenges by efficiently processing and analyzing extensive datasets from diverse sources including electronic health records, social media, and clinical trials.

This review explores the application of AI in PV, highlighting its ability to enhance the detection, reporting, and management of adverse drug reactions (ADRs). AI systems can automate routine tasks, transform unstructured data into actionable insights, and identify subtle safety signals that might elude human experts. However, the adoption of AI in PV is not without obstacles. Challenges such as data quality, privacy concerns, the need for robust training datasets, and the regulatory and ethical implications of AI decision-making processes must be addressed to fully harness its potential.

The review further discusses the necessity of integrating AI into existing PV frameworks, emphasizing the importance of collaboration among regulatory bodies, pharmaceutical companies, and healthcare providers. By examining the strengths and weaknesses of AI in PV, this paper aims to provide a comprehensive overview of the current landscape and future directions, advocating for a balanced approach that enhances human expertise with intelligent technology.

Keywords: Artificial Intelligence (AI), Pharmacovigilance (PV), Adverse Drug Reactions (ADRs), Individual Case Safety Reports (ICSRs), Regulatory Approval, AI Challenges in PV.

Introduction

A new era is dawning with artificial intelligence (AI). Unbeknownst to us, technology has ingrained itself into every aspect of our life, from the house to the streets, and it is now present in pharmacovigilance (PV), medical research, and the healthcare system [1]. By handling reports of potential adverse reactions and extracting health data to find drug safety signals, PV seeks to minimize the incidence and risk related to medication use as soon as possible. Individual case safety reports (ICSRs) have been used to systematically and systematically compile postmarketing safety reports of medical devices from all over the world using a spontaneous reporting mechanism[2].

Although they contain unstructured language, complementary data sources for routine PV activities include registries, published medical literature, pharmacoepidemiology research, electronic health-care records, and quarterly safety update reports. Pharmacovigilance is the area of science and activities concerned with the detection, assessment, understanding and prevention of adverse effects and any other drug related problems and is a fundamental aspect of public health and drug safety. Conventional methods of pharmacovigilance include the spontaneous reporting method, clinical trial or post – marketing surveillance, symptomatic examination. As such, these traditional approaches encounter various problems like underestimation of events, lack of timeliness of these events' identification, and the large amount of data that requires analysis[3].

The use of advanced technology and, particularly, the introduction of artificial intelligence (AI) within the recent years, various prospects in the field of pharmacovigilance have been opportunities to advance significantly in how ADRs are identified, reported, and handled. Machine learning, natural language processing, and other similar techniques that comprise AI have the potential to revolutionalize pharmacovigilance systems[4]. AI play a vital role by capturing the massive quantities of data through data mining from various sources which are very large and complex such as digital health records, social media, and clinical trial results. This is a clear indication that integration of AI technology has the potential to enhance the efficiency and effectiveness of activities associated with pharmacovigilance by accurately identifying patterns that are likely to emerge and therefore, necessary interventions[5].

For example, the machine learning algorithms can search millions of examples and identify weak signs of detrimental occurrences that people do not spot. Conventional format text data on clinical literature, social media platforms, and patients' records can also offer a broader view into drug risk profiles through natural language processing. However, these innovative trends do not come without their drawbacks, specifically in the case of implementing artificial intelligence in the field of pharmacovigilance. Critics argue that numerous concerns that center on data quality, privacy of the information used to feed the AI systems as well as understanding the decisions that the algorithms arrived at slows down the level of uptake[6]. It is essential to maintain reliability and validity of the outcomes obtained through the implementation of AI technologies, gain regulatory approval for the estimated technologies, and create sound guidelines and rules for the ethical usage of the estimated technologies in pharmacovigilance.In addition, the integration of AI system to the PV system should incorporate the existing PV systems and interfaces that are developed and thus there is the need for co-ordination with the all the stakeholders including but not limited to the regulatory institutions, the manufacturers, and the we providers[7-10].

This paper's objective it to discuss the specific case and utility of machine learning in pharmacology as well as to specify the further functions of AI in the subject of pharmacovigilance. It starts with the background from the view point of drug safety monitoring, the potentials that can be derived in terms of the goal, the challenges that need to be addressed to harness these potentials, the future outlook on the new avenue of AI based research and application. In this review, various qualities that can define AI as well as the drawback of utilizing it for the future of pharmacovigilance and overall health safety are discussed to portray both the strength and weaknesses available in the literature[11].

2.The necessity of artificial intelligence in pharmacovigilance

The number of reports of suspected adverse events (AEs) in the PV database has grown exponentially [Figure 1]. Key players including pharmaceutical companies, regulatory bodies, medical and PV specialists, and National Pharmacovigilance Program managers have challenges in processing the vast volume and variety of data sources, making sense of them, and sorting the "needles from the haystack[12]." Traditionally, the essential factors (patient, reporter, adverse reaction, suspected and concurrent drugs, and result) are required for the case processing of ICSR. Additionally, the prescribing information leaflet's expectations for adverse events (AEs), the possibility of a causal association, and the degree and seriousness of the case are assessed throughout the processing of ICSR cases[13]. criteria, and lastly examine to ensure validity and completeness for submission to the regulatory body. Crucially, it includes both manual labor and human thought [Figure 2][14].

In essence, it is costly and time-consuming because it requires a staff and technological know-how. There has been a lot of excitement and eagerness to use AI technology to automate PV in order to handle this growing burden[15].



Fig.1 The number of individual case safety reports that the WHO Global Database and the Pharmacovigilance Program of India (PvPI) have received has skyrocketed in recent years. Sources: MoHFW, IPC, and PvPI.information as of 10 October 2023. IPC stands for Indian Pharmacopoeia Commission; PvPI stands for Pharmacovigilance Program of India; MoHFW stands for Ministry of Health and Family Welfare; and ICSR stands for Individual Case Safety Report.

3.Artificial intelligence

Background

Computer science includes AI as a subfield. An artificial intelligence system leverages an algorithm and a library of facts to simulate human behavior, including comprehension, creativity, speech recognition, and decision-making.[16] Just like a toddler learns through instruction and training from their surroundings to become an intelligent human being, a machine gains human intelligence by learning and training using a vast volume of reliable datasets[17]. In order to educate computers to process data like neurons in the human brain and solve a specific problem that calls for human comprehension and reasoning, the new technology uses deep learning and natural language processing techniques.It's interesting to note that the computer generates an expert algorithm that can read both structured and unstructured text, extract information from unstructured text, and identify both simple and complex patterns in text and pictures to provide precise insights for image interpretation and the prediction of medication safety concerns[18]. Essentially, the training datasets and models that dictate the effectiveness and result of AI constitute the foundation for these machines' predictions. AI has demonstrated remarkable effectiveness in medical areas like radiology, ophthalmology, and pathology that rely on the interpretation of pictures[19].



Fig.2 Pharmacovigilance case processing and review of individual case safety reports. ADR stands for adverse drug response; ICSR is for individual case safety report.

4.Artificial intelligence tools applied in pharmacovigilance

Advantages and prospects

It has been suggested that the AI tool will help with the manual, repetitive, and routine tasks of data entry, drug-drug interactions, AE identification, subtle data patterns, and single case reviews.[20] Furthermore, AI has the ability to transform handwritten papers and unstructured, free-text drug safety data into a machine-readable format[21,22].Additionally, the program may identify serious reports and remove non-serious reports, verify duplicate reports, sort reports into physician or consumer reports, and automate the coding of the Medical Dictionary for Regulatory Activities [23].It's interesting to note that the AI platform can also identify patterns within structured and unstructured narratives, analyze unstructured data, extract text, and identify pertinent information to build clinically robust auto-narratives[24].

This eliminates the need for manual signal identification and validation as well as routine case reviews[25]. Additionally, it is capable of extracting ICSR data from a wide range of published sources, including case studies, medical publications, social media medicine reviews, free-text clinical notes in electronic health records, and discharge summaries[26].According to a recent poll, scientists can save time and money by using AI technologies to digest data quickly and expedite computations that were previously impractical[27]. The use of AI technologies will decrease case processing efforts, costs, and times, increase data quality, and might potentially revolutionize PV activities due to the vast volume of drug safety data that is kept in an electronic format [Table 1].

5. Obstacles in adopting artificial intelligence in pharmacovigilance

Although this tool shows promise, there are a number of issues and difficulties with its use and real-world impact [Table 1][28]. Is the AI algorithm's qualitative evaluation, which determines causation and safety signals by combining clinical examination and expert opinion, superior to that of human experts in making decisions is it possible to discover black swans using an AI system that is incorporated throughout the PV lifecycle? Will PV experts be totally replaced by it? It doesn't seem like there are any easy, clear solutions. Let us examine them from the perspectives of PV case processing and implementation within the framework of the healthcare systems in India[29-31].

5.1. Scientific challenges

Analysis and forecasting

Processing AE cases in PV is a difficult procedure that calls for several decision-making stages as well as adjudication inside of a system that is regulated and subject to audits [32]. For the purposes of determining causality and identifying signals, clinical examination and the clinician's perspective have unquestionably been important. The evaluation of AE's causality is primarily based on professional opinion and worldwide reflection[33-34] .The field of medicine and therapeutics is dynamic and multifaceted. The evaluation of ICSRs is not a computer-implementable, uniform, or standardized procedure. In actuality, decision-making usually necessitates human participation and clinical review due to variances in the patients' clinical presentations and side effects. The main inquiry is whether the current AI tool is robust enough to guarantee generalizability and quality performance while ensuring temporality, causal linkage, probable drug-drug interaction prediction, and safety alarm flagging in real-world data processing [35].

According to Huysentruyt et al., full AI automation of PV is still being developed for harmonization and best practices[36]. It is improper and dangerous to use AI tools to diverse, complex data in order to fully automate processes. Entire PV system automation to identify these intricate patterns could be deceptive and imprecise. This raises even another accountability issue. Who will be held accountable in the event that an AI tool, after being extensively validated, makes a mistake—the regulator, the tech company, or the developer. It's crucial that AI technology be adaptable and understand that complicated, challenging case circumstances require expert judgment to evaluate. However, the researchers have cautioned against the careless application of AI tools in science, as this might result in errors and false positives, wasting time and money[37]. Interestingly, the Uppsala Monitoring Center, which offers technical assistance and direction to the WHO Program for International Drug Monitoring, stressed that the Bayesian approach for automated disproportionality analysis for data mining should not take the place of thorough clinical examination when it was first introduced[38].

The similar operational approach is used by India, one of the participating nations in the WHO Program for International Drug Monitoring. The value of clinical assessment and human interaction in PV data processing cannot be overstated by the use of contemporary tools and technology. Complete photovoltaic system automation is a two-edged sword that requires careful consideration of people and procedures. The goal should be to enhance human talent in a way that achieves the PV system's objective and benefits all stakeholders through a cooperative strategy that combines technical competence (people) with intelligent technology (processes)[39].

5.2 Technological challenges

validation and training datasets

Training datasets are essential to this amazing technology since they are used to generate AI algorithms. For the method to be reliable and valid in real-world scenarios, the dataset must be large and varied, spanning all report types, from many sources, and representing the entire global population[40].For this to happen, datasets must be integrated, linked, annotated, labeled, and maintained in order to teach and train the computers from conception to completion. The training model must then be put to the test and approved before being used with actual data.

India possesses a well-established database and PV system. However, because of selective and underreported reporting, it does not accurately reflect actual adverse events (AEs) that occur in real life[41]. In order to yield high-quality evidence for causal association and signal detection, spontaneous adverse event reports must be linked to electronic health records of public and private sector hospitals, general practice records, disease registries, and published medical literature. Regretfully, most public and private hospitals in India maintain their medical data using antiquated systems, which may make it difficult to access, retrieve, or ensure the information is accurate. Integration and linking of data from various sources would also be hampered by India's disjointed healthcare system and disparate administrative structures.In India, very few superspecialty hospitals have started creating disease-specific registries, even though they need a lot of work to ensure quality, completeness, and connectivity[42].

Due to ethnic variance, pre-made datasets created by technology companies in industrialized nations cannot be applied to the Indian patient population without risk of bias and inaccurate predictions. Similar to this, a training dataset created from a single source that represents a patient population that is underrepresented or underserved, among other reasons, may bring systematic bias in addition to the possibility of unfairness and inequities[43-45]. The AI tool's forecast may be deceptive and imprecise if the data are not comprehensive, encompassing both public and private health-care sectors, accurately portraying all diseases and therapeutic areas, and sufficiently representing all patient demographics and ethnic groups.

When flagging possible drug safety signals, an algorithm should be very consistent, reproducible, sensitive, specific, and valid. In addition to identifying AEs, PV also aims to identify statistical outliers and enumerate dependent and contributing factors. When a small group of patients with negative experiences come together, it sends a crucial signal regarding causality and can shield at-risk patients from further harm after exposure. A low sensitivity algorithm would overlook safety alerts and possibly significant adverse events[46].

A low-specificity AI program would detect false-positive reports that generate background noise, making it challenging to locate signals. Furthermore, as medical knowledge and therapies progress, the algorithm will require frequent updates, retraining, and revalidation. However, the published literature has documented significant heterogeneity in the performance of AI algorithms for case processing, severity evaluation, and

causality assessment[47]. In actuality, the algorithm ought to be clever, adaptable, and dynamic in order to recognize complicated situations that call for human judgment and enhance qualitative assessment. However, specialized algorithms for conditions like Stevens-Johnson syndrome, drug-induced liver function alterations, and noncardiac medications inducing QTc prolongation might be more intriguing and helpful.

Technical aspects

Technical problems for data processing, labeling, and integration may arise from variations in the names of drugs and conditions, descriptions of adverse drug effects, diversity and challenges in local languages, ambiguities, and absence of information on self-medication (a prevalent practice). Language ambiguity and a medical word's various meanings or implications are among the main drawbacks[48]. For instance, "skin rashes" have over 20 possible causes, including drug-induced ones, making them a very frequent ailment. To identify, differentiate, and diagnose, however, specifics on its location, description, and accompanying signs and symptoms are needed. In the event where disparate PV data sources define "skin rashes" as an adverse event, the resulting choice and conclusion are likely to be incorrect. Words used in medicine to describe the same reactive term, like "skin rash and erythema" and "hypotension and orthostatic hypotension," may also cause confusion. Although the AI tool might be aware of various interpretations of a medical phrase, it might not be able to identify the exact meaning in the given context. This suggests that when reporters' descriptions and interpretations diverge, a case definition is necessary for accuracy.Similar to nonstandard and nonmedical terminology, slang, incorrect spellings, abbreviations, and missing crucial information, using social media safety data has its own disadvantages[49].

5.3 Moral considerations

In the absence of sufficient rules, the contentious issue is access to, ownership of, and use of specific patient data. Consent can jeopardize patient privacy, bring up moral questions, and erode confidence in the doctor-patient relationship. Images, sensitive data, and personal information about patients that are used for research should only be used with permission, anonymised to protect patient identity, and handled with care[50].

5.4 Regulatory issues

It's interesting to note that the US Food and Drug Administration (FDA) regulates all devices or computers that use artificial intelligence (AI) for clinical forecasts, diagnosis, prevention, and treatment of diseases. These tools are referred to as clinical decision support tools.The study of data bolstering FDA approval for critical care medical device applications, however, was found to have fallen short of expectations and criteria for independent validation and clinical efficacy assessment, according to a recent case series[51].This raises serious concerns and demonstrates the necessity of preapproval studies examining the safety, effectiveness, and validity of AI-based products created prior to the advancement of the field using statistical learning techniques.Although there are no explicit rules governing AI in India, the Indian Council of Medical Research has recently released Ethical Guidelines for Application of AI in Biomedical Research and Health[52].

Parallel to this, regulation of the use of AI technology to automate PV systems is necessary for quality assurance and validation. While the regulatory framework for AI use has not yet been specified by Indian regulatory authorities, laws are necessary to guarantee validation and accuracy for application in real-world contexts and for certain patient groups. Furthermore, laws are essential to strike a balance between the financial benefit and openness of technology companies and the safety of patients and the wellbeing of medical personnel[53].
Crucially, the legal framework must take into account the certification and approval process for adaptive AI systems over time, as new data become available and technology advances.

Ultimately, the basis of AI models is extremely intricate and resource-intensive. In order to train health-care professionals, a strong infrastructure for research and development is needed, as is a data infrastructure to create an extensive patient database. In order to invest in sustainable AI-based PV systems, research, training, and financial assistance from the government are all necessary. The nation will be forced to rely on AI tools created in resource-intensive nations without investment in research and development, which might be extremely expensive[54].

Conclusion

In conclusion, the advent of artificial intelligence (AI) in pharmacovigilance (PV) marks a transformative era in drug safety monitoring and healthcare. As the volume of adverse event (AE) reports continues to grow exponentially, AI offers promising solutions to the challenges faced by traditional PV methods. Through advanced technologies such as machine learning and natural language processing, AI can enhance the efficiency, accuracy, and speed of data processing, thereby improving the identification, reporting, and management of adverse drug reactions (ADRs).
AI's potential to revolutionize PV lies in its ability to handle vast and complex datasets, automate routine tasks, and uncover subtle data patterns that might elude human analysts. By transforming unstructured text and handwritten documents into machine-readable formats, AI can facilitate more comprehensive and robust drug safety assessments. Moreover, AI tools can streamline case processing, reduce manual labor, and lower costs, ultimately enhancing the overall quality of PV activities. However, the integration of AI in PV is not without its challenges. Scientific, technological, and ethical issues must be addressed to ensure the reliable and valid application of AI in real-world scenarios. Concerns about data quality, privacy,

and the interpretability of AI-generated decisions highlight the need for careful consideration and regulatory oversight. Establishing comprehensive training datasets, ensuring continuous algorithm updates, and maintaining a balance between human expertise and automated processes are crucial for the successful implementation of AI in PV.

Despite these challenges, the future of AI in pharmacovigilance is promising. By fostering collaboration among regulatory bodies, pharmaceutical companies, healthcare providers, and AI developers, the PV system can harness the full potential of AI technology. With robust guidelines, ethical standards, and ongoing investment in research and development, AI can significantly enhance drug safety monitoring, ultimately safeguarding public health and advancing the field of pharmacovigilance. The journey ahead requires a concerted effort to integrate AI seamlessly into existing PV frameworks, ensuring that the benefits of this innovative technology are fully realized while addressing its inherent limitations.

Acknowledgements

Authors (Mayuri G.Zore) are greatful to, Priya M. Dandekar, Shamli K. Ingle ,Shivam R. Ingle, Shivam K. Kathale ,Vaibhav V.Bakale, Atish N.Dhakane.

REFERENCES

1. Aronson JK. Artificial intelligence in pharmacovigilance: An introduction to terms, concepts, applications, and limitations. Drug Saf 2022;45:407-18.
2. Ibrahim H, Abdo A, El Kerdawy AM, Eldin AS. Signal detection in pharmacovigilance: A review of informatics-driven approaches for the discovery of drug-drug interaction signals in different data sources. Artif Intell Life Sci 2021;1:100005.
3. Bate A, Luo Y. Artificial intelligence and machine learning for safe medicines. Drug Saf 2022;45:403-5.
4. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med 2022;28:31-8.
5. Bhatt A. Artificial intelligence in managing clinical trial design and conduct: Man and machine still on the learning curve? Perspect Clin Res 2021;12:1-3.
6. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf 2021;44:125-32.
7. Henry S, Buchan K, Filannino M, Stubbs A, Uzuner O. 2018 n2c2 shared task on adverse drug events and medication extraction in electronic health records. J Am Med Inform Assoc 2020;27:3-12.
8. Sujith T, Chakradhar T, Sravani M, Sowmini K. Aspects of utilization and limitations of artificial intelligence in drug safety. Asian J Phar Clin Res 2021;14:34-9.
9. Luo Y, Thompson WK, Herr TM, Zeng Z, Berendsen MA, Jonnalagadda SR, et al. Natural language processing for EHR-Based pharmacovigilance: A structured review. Drug Saf 2017;40:1075-89.
10. Negi K, Pavuri A, Patel L, Jain C. A novel method for drug – Adverse event extraction using machine learning. Inf Med Unlocked 2019;17;100190.
11. Van Noorden R, Perkel JM. AI and science: What 1,600 researchers think. Nature 2023;621:672-5.
12. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf 2008;31:21-37.
13. Ralph Edwards I. Causality assessment in pharmacovigilance: Still a challenge. Drug Saf 2017;40:365-72.
14. Huysentruyt K, Kjoersvik O, Dobracki P, Savage E, Mishalov E, Cherry M, et al. Validating intelligent automation systems in pharmacovigilance: Insights from good manufacturing practices. Drug Saf 2021;44:261-72.
15. Mockute R, Desai S, Perera S, Assuncao B, Danysz K, Tetarenko N, et al. Artificial intelligence within pharmacovigilance: A means to identify cognitive services and the framework for their validation. Pharmaceut Med 2019;33:109-20.

16. Desai M. Pharmacovigilance and spontaneous adverse drug reaction reporting: Challenges and opportunities. Perspect Clin Res 2022;13:177-9.

17. Bhardwaj P. National quality registry for India: Need of the hour. Indian J Community Med 2022;47:157-8.

18. Larrazabal AJ, Nieto N, Peterson V, Milone DH, Ferrante E. Gender imbalance in medical imaging datasets produces biased classifiers for computer-aided diagnosis. Proc Natl Acad Sci U S A 2020;117:12592-4.

19. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science 2019;366:447-53.

20. Ball R, Dal Pan G. "Artificial Intelligence" for pharmacovigilance:Ready for prime time? Drug Saf 2022;45:429-38.

21. Brown EG, Harrion JE. Dictionaries and Coding in pharmacovigilance. In: Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th ed. Oxford: Wiley Blackwell; 2011. p. 545-72.

22. Pappa D, Stergioulas LK. Harnessing social media data for pharmacovigilance: A review of current state of the art, challenges and future directions. Int J Data Sci Anal 2019;8:113.

23. Kumar T, Sharma P, Singha M, Singh J. Big data analytics and pharmacovigilance-an ethical and legal consideration. Curr Trends Diagn Treatment 2018;2:58-65.

24. Lee JT, Moffett AT, Maliha G, Faraji Z, Kanter GP, Weissman GE. Analysis of devices authorized by the FDA for clinical decision support in critical care. JAMA Intern Med 2023;183:1399-401.

25. Habib AR, Gross CP. FDA regulations of AI-Driven clinical decision support devices fall short. JAMA Intern Med 2023;183:1401-2. Chino Y. AI in medicine: Creating a safe and equitable future. Lancet 2023;402:503.

26. Aronson JK. Artificial intelligence in pharmacovigilance: an introduction to terms, concepts, applications, and limitations. Drug Safety. 2022 May;45(5):407-18.

27. Salas M, Petracek J, Yalamanchili P, Aimer O, Kasthuril D, Dhingra S, Junaid T, Bostic T. The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. Pharmaceutical medicine. 2022 Oct;36(5):295-306.

28. Martin GL, Jouganous J, Savidan R, Bellec A, Goehrs C, Benkebil M, Miremont G, Micallef J, Salvo F, Pariente A, Létinier L. Validation of artificial intelligence to support the automatic coding of patient adverse drug reaction reports, using nationwide pharmacovigilance data. Drug Safety. 2022 May;45(5):535-48.

29. Hauben M. Artificial intelligence and data mining for the pharmacovigilance of drug–drug interactions. Clinical Therapeutics. 2023 Feb 1;45(2):117-33.

30. Desai MK. Artificial intelligence in pharmacovigilance–Opportunities and challenges. Perspectives in Clinical Research. 2024:10-4103.

31. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance: practical utility. Indian Journal of Pharmacology. 2019 Nov 1;51(6):373-6.

32. Pilipiec P, Liwicki M, Bota A. Using machine learning for pharmacovigilance: a systematic review. Pharmaceutics. 2022 Jan 23;14(2):266.

33. Lamprecht IV. An investigation into the prospects of existing technologies to address the challenges faced in pharmacovigilance systems (Doctoral dissertation, Stellenbosch: Stellenbosch University).

34. Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opinion on Drug Safety. 2015 Jan 2;14(1):63-72.

35. Huysamen B. A decision support tool to facilitate the development of a pharmacovigilance system within the context of the Medicine Patent Pool (Doctoral dissertation, Stellenbosch: Stellenbosch University).

36. Bahri P. Pharmacovigilance‐Related Topics at the Level of the International Conference on Harmonisation. Mann's Pharmacovigilance. 2014 Apr 1:47-62.

37. Anaedu PC. Challenges impacting the reporting of Adverse Drug Reactions among healthcare professionals: Improving pharmacovigilance in Nigeria.

38. Amran MS. Adverse drug reactions and pharmacovigilance. InNew insights into the future of pharmacoepidemiology and drug safety 2021 Oct 3. IntechOpen.

39. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance, an essential tool.

40. Al-Worafi YM, editor. Drug safety in developing countries: Achievements and challenges.

41. Fokunang ET, Fonmboh DJ, Mballa RN, Nyuyki AB, Fokunang LB, Kaba N, Abong TB, Duerr R, Richard E, Ondoua MT, Fokunang CN. Pharmacovigilance of natural herbal medicines research for efficacy, safety and quality assurance of phytomedicine products. J. Complement. Altern. Med. Res. 2020:21-37.

42. Schurer MJ. Towards the interoperability of spontaneous reporting systems in pharmacovigilance: A maturity model approach with a sociotechnical system focus (Doctoral dissertation, Stellenbosch: Stellenbosch University).

43. Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, Chan K, Shaw D, Duez P. Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. Journal of ethnopharmacology. 2012 Apr 10;140(3):519-25.

44. De Las Salas R, Soto CM. Pharmacovigilance in pediatric population. InPharmacovigilance 2019 Feb 9. IntechOpen.

45. Tissot M, Valnet-Rabier MB, Stalder T, Limat S, Davani S, Nerich V. Epidemiology and economic burden of "serious" adverse drug reactions: Real-world evidence research based on pharmacovigilance data. Therapies. 2022 May 1;77(3):291-300.

46. Olivera ME, Uema SA, Romañuk CB, Caffaratti M, Mastroianni PC, Varallo FR, Vazquez M, Fagiolino P, Maldonado C, Vega EM, Galvan ZV. Regulatory issues on pharmacovigilance in Latin American countries. Pharmaceuticals Policy and Law. 2014 Jan 1;16(3-4):289-312.

47. Hamumy FS. Knowledge, Attitude And Practice Of Pharmacovigilance Among Health Care Professionals At Kenyatta National Hospital (Doctoral dissertation, University of Nairobi).

48. Chowdhury S, Zhang C, Yu PS. Multi-task pharmacovigilance mining from social media posts. InProceedings of the 2018 World Wide Web Conference 2018 Apr 23 (pp. 117-126).

49. Ganguly B. Pharmacovigilance and Ethical Issues. GLOBAL BIOETHICS ENQUIRY. 2017 Sep:57.

50. Thompson A, Komparic A, Smith MJ. Ethical considerations in post-market-approval monitoring and regulation of vaccines. Vaccine. 2014 Dec 12;32(52):7171-4.

51. Moscou K, Kohler JC. Pharmacogovernance: Advancing pharmacovigilance and patient safety. InSocial and Administrative Aspects of Pharmacy in Low-and Middle-Income Countries 2018 Jan 1 (pp. 403-418). Academic Press.

52. Sharma R, Nandave M, Kumar A. Role of Pharmacogenetics in Pharmacovigilance. InPharmacovigilance Essentials: Advances, Challenges and Global Perspectives 2024 Apr 4 (pp. 317-331). Singapore: Springer Nature Singapore.

53. Jimmy PE. Ethical Challenges in Pain Management: Balancing Opioid Prescribing Practices and Patient Well-Being in Family Medicine.

54. Meli BA, Fenech AG, Cordina M, Ellul B, Agius E. Challenges in public policy for the implementation of pharmacogenetic tests in Europe. BioSocieties. 2024 Mar 16:1-8.